{
    "medicine_id": "b9c25c27e010e6dc975b94b3e757f5fee2445c82",
    "platform_id": "DB15935",
    "metadata": {
        "name": "Oxlumo 94 5 mg 0 5mL Injection solution",
        "composition": "94 5 mg 0 5mL Lumasiran",
        "clinical_particulars": {
            "therapeutic_indications": "Lumasiran is indicated for the treatment of primary hyperoxaluria type 1 L23394 L23519",
            "contraindications": {
                "disease": "Data regarding overdoses of lumasiran are not readily available L23519 In the event of an overdose patients should be monitored for signs of adverse reactions and be treated symptomatically L23519",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Lumasiran is a small interfering RNA that prevents the translation of glycolate oxidase which reduces levels of glyoxylate reducing metabolism of glyoxylate to oxalate L23404 L23519 The duration of action is long as it is given every 3 months L23519 Patients should be counselled regarding the risk of worsening metabolic acidosis in severe or end stage renal disease as well as potentially decreased efficacy in moderate to severe hepatic impairment L23519",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}